Anti-melanoma activity of T cells redirected with a TCR-like chimeric antigen receptor
about
T cell receptor mimic antibodies for cancer therapyTailoring the Treatment of Melanoma: Implications for Personalized MedicineThe advantages of PD1 activating chimeric receptor (PD1-ACR) engineered lymphocytes for PDL1(+) cancer therapyBlockade of Programmed Death 1 Augments the Ability of Human T Cells Engineered to Target NY-ESO-1 to Control Tumor Growth after Adoptive Transfer.New development in CAR-T cell therapy.Engineering CAR-T cells: Design concepts.A therapeutic T cell receptor mimic antibody targets tumor-associated PRAME peptide/HLA-I antigens.Opportunities and challenges for TCR mimic antibodies in cancer therapyNovel immunotherapies for the treatment of melanoma.Leukocyte-mediated Delivery of Nanotherapeutics in Inflammatory and Tumor Sites.Chimeric antigen receptor engineered stem cells: a novel HIV therapy.Engineering Chimeric Antigen Receptors.Current status and perspectives of chimeric antigen receptor modified T cells for cancer treatment.Therapeutic T cell engineering.Soluble HLA-associated peptide from PSF1 has a cancer vaccine potency.Therapeutic Antibodies against Intracellular Tumor AntigensNaturally Occurring Canine Melanoma as a Predictive Comparative Oncology Model for Human Mucosal and Other Triple Wild-Type Melanomas.Nanobody Based Dual Specific CARs.TCR-mimic bispecific antibodies targeting LMP2A show potent activity against EBV malignancies.An MHC-restricted antibody-based chimeric antigen receptor requires TCR-like affinity to maintain antigen specificity.VEGFR2-specific FnCAR effectively redirects the cytotoxic activity of T cells and YT NK cells.Immune Cell Hacking: Challenges and Clinical Approaches to Create Smarter Generations of Chimeric Antigen Receptor T Cells
P2860
Q26768271-8E204252-AA33-498F-BCF0-6273D13C147FQ26775806-B9F37AAD-3647-4D7D-8752-11880C78B053Q28646882-C08CF160-11A5-4854-B143-4A0096538085Q36471557-79018B59-BF1B-4E52-B62E-320532CF2FCFQ37658246-03A14BF0-ABC2-460B-B39F-E3377920BEB0Q38290031-26691631-10AD-4719-BF08-5917C0A9ED98Q38719407-8B68F1E7-4499-48E0-883F-439C324A075EQ38812269-A1E50024-0A64-45E0-8A12-1724788C14B7Q38824190-4E98E605-23B0-4731-89BA-7A612FDD28D3Q39159035-48A34859-8135-4992-A504-F0C8900B43D3Q39208504-B3320611-4F8E-4886-A2C7-55839F504C30Q39276909-A5080539-F35B-40A8-93A8-FDD189D469BFQ39280002-1962681A-9518-4DDA-AFD6-69AE7074F770Q40199809-AB601E0E-E7B7-4630-B082-1E4BF3757EA8Q41325257-71A8335F-40D1-4B6D-A2B0-D333F43AE340Q41462883-41CCB4D3-12C6-4594-8B9F-EC9BDCA127BBQ47547587-01569F91-C09A-4BAB-B251-DA53D50D89B2Q48132569-EE008F5C-B62F-484F-B63D-04F70A9A8702Q52691571-4647F0D1-B009-4C26-95C7-604ED4466FAFQ52804817-07604941-3836-46C2-8598-38479F37DD3AQ55129555-B568F368-367F-4F44-BCA5-91DE8B27C8C7Q57173949-23512047-C43A-4D9A-9F2B-5513C4397DB8
P2860
Anti-melanoma activity of T cells redirected with a TCR-like chimeric antigen receptor
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 06 January 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Anti-melanoma activity of T cells redirected with a TCR-like chimeric antigen receptor
@en
Anti-melanoma activity of T cells redirected with a TCR-like chimeric antigen receptor.
@nl
type
label
Anti-melanoma activity of T cells redirected with a TCR-like chimeric antigen receptor
@en
Anti-melanoma activity of T cells redirected with a TCR-like chimeric antigen receptor.
@nl
prefLabel
Anti-melanoma activity of T cells redirected with a TCR-like chimeric antigen receptor
@en
Anti-melanoma activity of T cells redirected with a TCR-like chimeric antigen receptor.
@nl
P2093
P2860
P356
P1433
P1476
Anti-melanoma activity of T cells redirected with a TCR-like chimeric antigen receptor
@en
P2093
Changzhen Liu
Ganlin Zhang
Honglian Cui
Huamin Han
P2860
P2888
P356
10.1038/SREP03571
P407
P577
2014-01-06T00:00:00Z